首页> 美国卫生研究院文献>Therapeutic Advances in Urology >Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study
【2h】

Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study

机译:伴有良性前列腺增生症的男性患者的王冠脂脂质提取物(D-004)和特拉唑嗪的疗效和耐受性:一项为期6个月的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background:Benign prostatic hyperplasia (BPH), a common urological disease in aging men, frequently produces lower urinary tract symptoms (LUTS). Clinical studies have shown that terazosin relaxes the smooth muscle of the prostate and bladder, facilitates bladder emptying, improves LUTS, increases maximum urinary flow, and reduces the residual volume of urine. D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia), presents a similar efficacy to Saw palmetto. Clinical studies have demonstrated its efficacy and safety in short- and medium-term trials in patients with BPH. The objective of this study was to compare the efficacy and tolerability of D-004 with terazosin for 6 months on LUTS in patients with BPH.
机译:背景:良性前列腺增生(BPH)是老年男性常见的泌尿科疾病,经常产生下尿路症状(LUTS)。临床研究表明,特拉唑嗪可放松前列腺和膀胱的平滑肌,促进膀胱排空,改善尿路感染,增加最大尿流量,并减少尿液残留量。 D-004是古巴皇家棕榈(Roystonea regia)果实的脂质提取物,具有与锯棕榈一样的功效。临床研究已证明其在BPH患者的短期和中期试验中的有效性和安全性。这项研究的目的是比较D-004与特拉唑嗪对BPH患者6个月大的LUTS的疗效和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号